The Expression and Clinical Significance of TCP1 in Newly Diagnosed Acute Myeloid Leukemia Patients.
10.19746/j.cnki.issn.1009-2137.2025.02.005
- Author:
Jia-Jia LI
1
;
Yan-Ping WU
1
;
Lin LIU
1
;
Meng-Meng ZHANG
1
;
Meng WANG
1
;
Ping-Ping ZHANG
1
;
Feng ZHANG
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233003, Anhui Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
T-complex peptide 1;
prognosis
- MeSH:
Gene Expression Regulation, Leukemic;
Leukemia, Myeloid, Acute/metabolism*;
Humans;
Gene Expression Profiling;
Bone Marrow/metabolism*;
Anemia, Iron-Deficiency/metabolism*;
Polymerase Chain Reaction;
Prognosis;
Kaplan-Meier Estimate;
Proportional Hazards Models;
Multivariate Analysis;
Risk Factors;
Chaperonin Containing TCP-1
- From:
Journal of Experimental Hematology
2025;33(2):339-343
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect the expression level of T-complex polypeptide 1 (TCP1) in the bone marrow of newly diagnosed acute myeloid leukemia (AML) patients, and explore its correlation with clinical characteristics and prognosis.
METHODS:The bone marrow samples from 80 newly diagnosed AML patients and 30 iron deficiency anemia (IDA) patients were collected, and real time fluorescence quantitative PCR was used to detect the expression level of TCP1 . The clinical data of AML patients were collected, and the correlation of TCP1 expression with clinical characteristics and prognosis of patients were analyzed. The impact of TCP1 on overall survival (OS) of AML patients was identified by using Kaplan-Meier curve analysis. Cox regression analysis was used to identify the factors affecting prognosis of AML patients.
RESULTS:Compared with IDA patients, the expression of TCP1 was significantly increased in AML patients (P < 0.01). The high expression group of TCP1 showed a higher proportion of patients with ≥60 years and non-remission after treatment, more accompanied by TET2 mutation and poor prognosis but shorter OS compared to the low expression group (all P < 0.05). The results of multivariate Cox regression analysis showed that age, chromosomal abnormalities, therapeutic efficacy and TCP1 expression were independent risk factors affecting prognosis of AML patients (all P < 0.05).
CONCLUSION:TCP1 is significantly upregulated in AML patients, and its expression is associated with partial clinical features and poor prognosis. It can serve as a prognostic indicator and potential therapeutic target for AML patients.
